Barr in lawsuit over Razadyne patent
Generic drug maker Barr Pharmaceuticals Inc. is being sued by several companies in a patent dispute over the extended release version of Alzheimer''s drug, Razadyne, the Associated Press reports. Barr is being sued in New Jersey District Court by Johnson & Johnson unit Janssen Pharmaceutica N.V. and Synaptech Inc., the new drug application holder and patent owner respectively, as well as Ortho-McNeil Neurologics Inc., the marketing company for the drug. Barr challenged the patent by filing an abbreviated new drug application with the U.S. Food and Drug Administration for three different doses in March. The lawsuit comes a year after Barr challenged the same companies on the immediate release form of the drug. That patent lawsuit is still active. The extended release version of Razadyne, launched in May 2005, brought in sales of approximately $54 million in the first 12 months, Barr said.